Online inquiry

IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2623MR)

This product GTTS-WQ2623MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOSLG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001283050.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23308
UniProt ID O75144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2623MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6930MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ15085MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ9472MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ1628MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ1420MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ12678MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ3428MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ9836MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW